AAP
IKT icon

Arax Advisory Partners’s Inhibikase Therapeutics IKT Stock Holding History

Arax Advisory Partners’s Portfolio IKT Stock Details IKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$14.5K Buy
7,121
+7,072
+14,433% +$12.7K ﹤0.01% 4165
2026
Q1 		$82 Buy
+49
New +$87 ﹤0.01% 3629
2025
Q4 		– Sell
-86
Closed -$139 – 4294
2025
Q3 		$139 Buy
+86
New +$149 ﹤0.01% 3477

Other funds holding IKT

SCV
Sands Capital Ventures Arlington, Virginia $614M AUM 19.92% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Arax Advisory Partners's IKT Position: Q2 2026 in Review

Arax Advisory Partners increased its Inhibikase Therapeutics (IKT) stake by 14,433% in Q2 2026, buying an estimated $12.7K and bringing the position to 7,121 shares worth $14.5K. The position accounts for ﹤0.01% of the portfolio, ranked #4165.

Arax Advisory Partners first reported a position in IKT in Q3 2025 and has held it in 3 quarters since. 106 funds tracked by Wall St. Rank hold IKT as of Q2 2026.

  • Arax Advisory Partners held 7,121 shares of Inhibikase Therapeutics worth $14.5K as of Q2 2026.
  • Arax Advisory Partners bought 7,072 Inhibikase Therapeutics shares in Q2 2026, an estimated $12.7K.
  • Inhibikase Therapeutics made up ﹤0.01% of Arax Advisory Partners's portfolio in Q2 2026, its #4165 holding.
  • Arax Advisory Partners first reported a position in Inhibikase Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • 106 funds tracked by Wall St. Rank held Inhibikase Therapeutics as of Q2 2026.

Based on Arax Advisory Partners's 13F filing for Q2 2026, filed 10 Aug 2026.